TapewireFind a company

person · Reporting owner

Mathers Edward T

Disclosed activity across 17 companies

Tapewire entity
24544
SEC CIK
0001328625

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Inozyme Pharma, Inc.INZY · Entity 77717DirectorJune 18, 2024June 20, 2024
Liquidia Technologies IncLQDA · Entity 145051DirectorJuly 25, 2018July 27, 2018
MBX Biosciences, Inc.MBX · Entity 4247DirectorJune 04, 2026June 05, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416DirectorJune 02, 2022June 06, 2022
Monte Rosa Therapeutics, Inc.GLUE · Entity 482810% ownerJune 28, 2021June 30, 2021
ObsEva SAOBSV · Entity 114543DirectorJanuary 01, 2023January 03, 2023
OnKure Therapeutics, Inc.OKUR · Entity 6550DirectorAugust 07, 2026August 11, 2026
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693DirectorMarch 12, 2026March 16, 2026
SYNLOGIC, INC.SYBX · Entity 7801DirectorJune 22, 2023June 26, 2023
Savara IncSVRA · Entity 490010% ownerJuly 17, 2023July 19, 2023
Senti Biosciences Holdings, Inc.SNTI · Entity 7935DirectorJune 25, 2025June 27, 2025
SpyGlass Pharma, Inc.SGP · Entity 503410% ownerFebruary 09, 2026February 11, 2026
Trevi Therapeutics, Inc.TRVI · Entity 4387DirectorJune 03, 2026June 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inozyme Pharma, Inc.

Report date June 18, 2024 · Filed June 20, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2034-06-17Direct28,000 Reported balance After 2024-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-06-18 · Grant · Acquired 28,000 · Balance 28,000

F1: The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

Liquidia Technologies Inc

Report date July 25, 2018 · Filed July 27, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2028-07-25Direct26,986 Reported balance After 2018-07-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-07-25 · Grant · Acquired 26,986 · Balance 26,986

F1: 2.778% of such stock options vest on August 25, 2018 and on such date every month thereafter, through the third anniversary of August 25, 2018, subject to Mr. Mathers' continuous service as of each such date.

Filing footnotes · ownership attribution and instrument terms

F1: 2.778% of such stock options vest on August 25, 2018 and on such date every month thereafter, through the third anniversary of August 25, 2018, subject to Mr. Mathers' continuous service as of each such date.

MBX Biosciences, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.91 · Expires 2036-06-04Direct12,500 Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-04 · Grant · Acquired 12,500 · Balance 12,500

F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

Filing footnotes · ownership attribution and instrument terms

F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

Mirum Pharmaceuticals, Inc.

Report date June 02, 2022 · Filed June 06, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.51 · Expires 2032-06-01Direct17,000 Reported balance After 2022-06-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-06-02 · Grant · Acquired 17,000 · Balance 17,000

F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting.

Monte Rosa Therapeutics, Inc.

Report date June 28, 2021 · Filed June 30, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Note 27,692,298 Last balance in matching sequence After 2021-06-28 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rows

Row 1 · 2021-06-28 · Conversion · Acquired 2,715,968 · Balance 2,715,968

F1: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 2 · 2021-06-28 · Conversion · Acquired 3,257,328 · Balance 5,973,296

F1: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 3 · 2021-06-28 · Conversion · Acquired 669,002 · Balance 6,642,298

F1: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 4 · 2021-06-28 · Purchase · Acquired 1,050,000 · Balance 7,692,298

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series A-2 convertible preferred stockSEC Table II · derivative / convertible securityIndirectSee Note 20 Reported balance After 2021-06-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2021-06-28 · Conversion · Disposed 9,588,725 · Balance 0

F1: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series B convertible preferred stockSEC Table II · derivative / convertible securityIndirectSee Note 20 Reported balance After 2021-06-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2021-06-28 · Conversion · Disposed 11,500,000 · Balance 0

F1: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series C convertible preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 20 Reported balance After 2021-06-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2021-06-28 · Conversion · Disposed 2,361,912 · Balance 0

F1: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

ObsEva SA

Report date January 01, 2023 · Filed January 03, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-01-24DirectNot disclosed Reported balance Holding disclosure · report date 2023-01-01 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: Fully vested and exercisable.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2027-12-06DirectNot disclosed Reported balance Holding disclosure · report date 2023-01-01 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F1: Fully vested and exercisable.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2028-11-26DirectNot disclosed Reported balance Holding disclosure · report date 2023-01-01 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F1: Fully vested and exercisable.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2030-01-27DirectNot disclosed Reported balance Holding disclosure · report date 2023-01-01 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F1: Fully vested and exercisable.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2031-02-03DirectNot disclosed Reported balance Holding disclosure · report date 2023-01-01 · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · Balance Not disclosed

F1: Fully vested and exercisable.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2032-02-01DirectNot disclosed Reported balance Holding disclosure · report date 2023-01-01 · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · Balance Not disclosed

F2: The shares underlying the option vested or will vest in 12 equal monthly installments from February 2, 2022, such that the option is fully vested on the one-year anniversary thereof, subject to the Reporting Person continuing to provide service through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Fully vested and exercisable.

F2: The shares underlying the option vested or will vest in 12 equal monthly installments from February 2, 2022, such that the option is fully vested on the one-year anniversary thereof, subject to the Reporting Person continuing to provide service through each such date.

OnKure Therapeutics, Inc.

Report date August 07, 2026 · Filed August 11, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06Direct22,350 Reported balance After 2026-08-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-08-07 · Grant · Acquired 22,350 · Balance 22,350

F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

RHYTHM PHARMACEUTICALS, INC.

Report date March 12, 2026 · Filed March 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Note 214,168 Reported balance After 2026-03-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2026-03-12 · Other · Acquired 4,199 · Balance 14,168

F1: NEA Partners 13, L.P. ("NEA Partners 13") made a pro rata distribution for no consideration of shares of Common Stock of the Issuer to its limited partners on March 12, 2026. The Edward Timothy Mathers Revocable Trust (the "Mathers Trust") received 4,199 shares of Common Stock of the Issuer in the distribution by NEA Partners 13 on March 12, 2026.

F2: The Reporting Person is the trustee of the Mathers Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by the Mathers Trust in which the Reporting Person has no pecuniary interest.

Common StockSEC Table I · non-derivativeDirect7,000 Reported balance Holding disclosure · report date 2026-03-12 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 7,000

Filing footnotes · ownership attribution and instrument terms

F1: NEA Partners 13, L.P. ("NEA Partners 13") made a pro rata distribution for no consideration of shares of Common Stock of the Issuer to its limited partners on March 12, 2026. The Edward Timothy Mathers Revocable Trust (the "Mathers Trust") received 4,199 shares of Common Stock of the Issuer in the distribution by NEA Partners 13 on March 12, 2026.

F2: The Reporting Person is the trustee of the Mathers Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by the Mathers Trust in which the Reporting Person has no pecuniary interest.

SYNLOGIC, INC.

Report date June 22, 2023 · Filed June 26, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-22Direct30,000 Reported balance After 2023-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000

F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

Savara Inc

Report date July 17, 2023 · Filed July 19, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Note 224,471,264 Reported balance After 2023-07-17 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2023-07-17 · Purchase · Acquired 333,333 · Balance 24,471,264

F1: Reports the purchase of shares in the underwritten public offering of common stock of the Issuer.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"). NEA 17 is the sole member of Growth Equity Opportunities 17, LLC ("GEO 17"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by GEO 17 in which the Reporting Person has no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Reports the purchase of shares in the underwritten public offering of common stock of the Issuer.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"). NEA 17 is the sole member of Growth Equity Opportunities 17, LLC ("GEO 17"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by GEO 17 in which the Reporting Person has no pecuniary interest.

Senti Biosciences Holdings, Inc.

Report date June 25, 2025 · Filed June 27, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2035-06-24Direct21,950 Reported balance After 2025-06-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-06-25 · Grant · Acquired 21,950 · Balance 21,950

F1: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.

SpyGlass Pharma, Inc.

Report date February 09, 2026 · Filed February 11, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Note 26,035,038 Last balance in matching sequence After 2026-02-09 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rows

Row 1 · 2026-02-09 · Conversion · Acquired 1,619,240 · Balance 1,619,240

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 2 · 2026-02-09 · Conversion · Acquired 1,370,168 · Balance 2,989,408

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 3 · 2026-02-09 · Conversion · Acquired 1,370,168 · Balance 4,359,576

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 4 · 2026-02-09 · Conversion · Acquired 737,962 · Balance 5,097,538

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 5 · 2026-02-09 · Purchase · Acquired 937,500 · Balance 6,035,038

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 20 Reported balance After 2026-02-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-02-09 · Conversion · Disposed 1,619,240 · Balance 0

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 20 Reported balance After 2026-02-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-02-09 · Conversion · Disposed 1,370,168 · Balance 0

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series C-2 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 20 Reported balance After 2026-02-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-02-09 · Conversion · Disposed 1,370,168 · Balance 0

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series D Preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 20 Reported balance After 2026-02-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2026-02-09 · Conversion · Disposed 737,962 · Balance 0

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Trevi Therapeutics, Inc.

Report date June 03, 2026 · Filed June 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2036-06-02Direct35,000 Reported balance After 2026-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-03 · Grant · Acquired 35,000 · Balance 35,000

F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Akouos, Inc.

Report date December 01, 2022 · Filed December 02, 2022

Section 16 reporting ended · disclosed 2022-12-02. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2032-06-22Direct0 Reported balance After 2022-12-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-12-01 · Disposition to issuer · Disposed 16,000 · Balance 0

F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and [Continued on Note 2]

F2: [Continuation of Note 1] (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.

Filing footnotes · ownership attribution and instrument terms

F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and [Continued on Note 2]

F2: [Continuation of Note 1] (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.

Korro Bio, Inc.

Report date March 10, 2026 · Filed March 13, 2026

Section 16 reporting ended · disclosed 2026-03-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Note 21,297,893 Reported balance After 2026-03-10 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2026-03-10 · Purchase · Acquired 207,100 · Balance 1,297,893

F1: Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Pre-Funded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee Note 2242,945 Reported balance After 2026-03-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-03-10 · Purchase · Acquired 242,945 · Balance 242,945

F1: Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

F3: The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

F3: The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

NeueHealth, Inc.

Report date October 02, 2025 · Filed October 06, 2025

Section 16 reporting ended · disclosed 2025-10-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Note 10 Last balance in matching sequence After 2025-10-02 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rows

Row 1 · 2025-10-02 · Other · Acquired 189,195 · Balance 488,982

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 2 · 2025-10-02 · Sale · Disposed 280 · Balance 488,702

F2: Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025.

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 3 · 2025-10-02 · Exercise / conversion · Acquired 186,128 · Balance 674,830

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 4 · 2025-10-02 · Tax withholding · Disposed 276 · Balance 674,554

F2: Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025.

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Row 5 · 2025-10-02 · Disposition to issuer · Disposed 674,554 · Balance 0

F3: Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. ("Parent") and NH Holdings Acquisition 2025, Inc. ("Merger Sub"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. ("Ultimate Parent"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist.

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Common StockSEC Table I · non-derivativeIndirectSee Note 40 Last balance in matching sequence After 2025-10-02 transaction · row 12 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rows

Row 6 · 2025-10-02 · Other · Acquired 1,656,789 · Balance 1,656,789

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Row 7 · 2025-10-02 · Sale · Disposed 2,455 · Balance 1,654,334

F2: Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Row 8 · 2025-10-02 · Other · Acquired 607,536 · Balance 2,261,870

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Row 9 · 2025-10-02 · Sale · Disposed 900 · Balance 2,260,970

F2: Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Row 10 · 2025-10-02 · Exercise / conversion · Acquired 124,085 · Balance 2,385,055

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Row 11 · 2025-10-02 · Tax withholding · Disposed 182 · Balance 2,384,873

F2: Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Row 12 · 2025-10-02 · Disposition to issuer · Disposed 2,384,873 · Balance 0

F3: Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. ("Parent") and NH Holdings Acquisition 2025, Inc. ("Merger Sub"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. ("Ultimate Parent"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01IndirectSee Note 10 Reported balance After 2025-10-02 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2025-10-02 · Other · Disposed 189,195 · Balance 0

F5: The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025.

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2030-10-02IndirectSee Note 1186,128 Reported balance After 2025-10-02 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2025-10-02 · Grant · Acquired 186,128 · Balance 186,128

F6: Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto.

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01IndirectSee Note 10 Reported balance After 2025-10-02 transaction · row 15 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 15 · 2025-10-02 · Exercise / conversion · Disposed 186,128 · Balance 0

F7: The warrants became fully exercisable on October 2, 2025.

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series A Convertible Perpetual Preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 10 Reported balance After 2025-10-02 transaction · row 16 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 16 · 2025-10-02 · Disposition to issuer · Disposed 75,000 · Balance 0

F8: The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions.

F3: Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. ("Parent") and NH Holdings Acquisition 2025, Inc. ("Merger Sub"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. ("Ultimate Parent"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist.

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Series B Convertible Perpetual Preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 10 Reported balance After 2025-10-02 transaction · row 17 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 17 · 2025-10-02 · Disposition to issuer · Disposed 37,700 · Balance 0

F9: The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions.

F3: Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. ("Parent") and NH Holdings Acquisition 2025, Inc. ("Merger Sub"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. ("Ultimate Parent"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist.

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01IndirectSee Note 40 Reported balance After 2025-10-02 transaction · row 18 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 18 · 2025-10-02 · Other · Disposed 1,656,789 · Balance 0

F10: The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01IndirectSee Note 40 Reported balance After 2025-10-02 transaction · row 19 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 19 · 2025-10-02 · Other · Disposed 607,536 · Balance 0

F11: The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2030-10-02IndirectSee Note 4124,085 Reported balance After 2025-10-02 transaction · row 20 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 20 · 2025-10-02 · Grant · Acquired 124,085 · Balance 124,085

F6: Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01IndirectSee Note 40 Reported balance After 2025-10-02 transaction · row 21 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 21 · 2025-10-02 · Exercise / conversion · Disposed 124,085 · Balance 0

F7: The warrants became fully exercisable on October 2, 2025.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Series A Convertible Perpetual Preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 40 Reported balance After 2025-10-02 transaction · row 22 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 22 · 2025-10-02 · Disposition to issuer · Disposed 125,000 · Balance 0

F8: The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions.

F3: Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. ("Parent") and NH Holdings Acquisition 2025, Inc. ("Merger Sub"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. ("Ultimate Parent"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Series B Convertible Perpetual Preferred StockSEC Table II · derivative / convertible securityIndirectSee Note 40 Reported balance After 2025-10-02 transaction · row 23 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 23 · 2025-10-02 · Disposition to issuer · Disposed 100,000 · Balance 0

F9: The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions.

F3: Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. ("Parent") and NH Holdings Acquisition 2025, Inc. ("Merger Sub"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. ("Ultimate Parent"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

F2: Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025.

F3: Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. ("Parent") and NH Holdings Acquisition 2025, Inc. ("Merger Sub"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. ("Ultimate Parent"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist.

F4: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

F5: The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025.

F6: Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto.

F7: The warrants became fully exercisable on October 2, 2025.

F8: The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions.

F9: The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions.

F10: The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023.

F11: The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025.

Ra Pharmaceuticals, Inc.

Report date April 02, 2020 · Filed April 03, 2020

Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.37 · Expires 2027-06-20Direct0 Reported balance After 2020-04-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.90 · Expires 2028-06-28Direct0 Reported balance After 2020-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.88 · Expires 2029-06-11Direct0 Reported balance After 2020-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 28, 2025 Filed May 30, 2025 21:05 UTC OnKure Therapeutics, Inc. OKUR · Entity 6550 GrantStock Option (right to buy) · Derivative 7,650 $0.00 Strike: $2.44 $0.00
Disclosure

SEC source: 0000950170-25-079841 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Class A Common Stock · 7,650 shares

Expires 2035-05-27

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 20:48 UTC OnKure Therapeutics, Inc. OKUR · Entity 6550 GrantClass A Common Stock 2,580 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-049473 · ownership.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,580

F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 20:28 UTC Senti Biosciences Holdings, Inc. SNTI · Entity 7935 GrantStock Option (Right to Buy) · Derivative 43,900 $0.00 Strike: $3.52 $0.00
Disclosure

SEC source: 0000950170-25-037187 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,900

Underlying: Common Stock · 43,900 shares

Expires 2035-03-06

F1 · derivative.exercise_date: 100% of the shares underlying this option vest on the first anniversary of the date of grant, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
October 04, 2024 Filed Oct 8, 2024 23:27 UTC OnKure Therapeutics, Inc. OKUR · Entity 6550 GrantStock Option (right to buy) · Derivative 15,300 $0.00 Strike: $18.20 $0.00
Disclosure

SEC source: 0000950170-24-113604 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,300

Underlying: Class A Common Stock · 15,300 shares

Expires 2034-10-03

F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
October 01, 2024 Filed Oct 3, 2024 22:37 UTC NeueHealth, Inc. NEUE · Entity 74308 PurchaseWarrant (Right to Buy) · Derivative 185,595 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0000950170-24-112614 · ownership.xml · derivative · entry 2

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 3

Disclosed balance after: 556,782

Underlying: Common Stock · 185,595 shares

Expires 2029-04-30

F1 · price: Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto.

F3 · ownership.nature: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
October 01, 2024 Filed Oct 3, 2024 22:37 UTC NeueHealth, Inc. NEUE · Entity 74308 PurchaseWarrant (Right to Buy) · Derivative 61,865 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0000950170-24-112614 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 185,594

Underlying: Common Stock · 61,865 shares

Expires 2029-04-30

F1 · price: Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:28 UTC MBX Biosciences, Inc. MBX · Entity 4247 ConversionSeries B Convertible Preferred Stock · Derivative 25,142,840 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-107558 · ownership.xml · derivative · entry 5

Mathers Edward T · CIK 0001328625 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 0

Underlying: Common Stock · 2,091,383 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:28 UTC MBX Biosciences, Inc. MBX · Entity 4247 ConversionSeries A Convertible Preferred Stock · Derivative 12,299,854 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-107558 · ownership.xml · derivative · entry 4

Mathers Edward T · CIK 0001328625 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 0

Underlying: Common Stock · 1,023,103 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:28 UTC MBX Biosciences, Inc. MBX · Entity 4247 PurchaseCommon Stock 500,000 $16.00 $8,000,000.00
Disclosure

SEC source: 0000950170-24-107558 · ownership.xml · nonDerivative · entry 3

Mathers Edward T · CIK 0001328625 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 3,614,486

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:28 UTC MBX Biosciences, Inc. MBX · Entity 4247 ConversionCommon Stock 2,091,383 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-107558 · ownership.xml · nonDerivative · entry 2

Mathers Edward T · CIK 0001328625 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 3,114,486

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:28 UTC MBX Biosciences, Inc. MBX · Entity 4247 ConversionCommon Stock 1,023,103 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-107558 · ownership.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 1,023,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
September 12, 2024 Filed Sep 13, 2024 21:11 UTC MBX Biosciences, Inc. MBX · Entity 4247 GrantStock Option (Right to Buy) · Derivative 15,963 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0000950170-24-106456 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,963

Underlying: Common Stock · 15,963 shares

Expires 2034-09-11

F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 20:30 UTC Senti Biosciences Holdings, Inc. SNTI · Entity 7935 GrantStock Option (Right to Buy) · Derivative 62,500 $0.00 Strike: $0.31 $0.00
Disclosure

SEC source: 0000950170-24-083230 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2034-07-09

F1 · derivative.exercise_date: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2025 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
June 21, 2024 Filed Jun 25, 2024 20:38 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 Exercise / conversionRestricted Stock Units · Derivative 3,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077346 · ownership.xml · derivative · entry 3

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date.

Read SEC document
June 21, 2024 Filed Jun 25, 2024 20:38 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 Exercise / conversionCommon Stock 3,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-077346 · ownership.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 16:30 UTC Inozyme Pharma, Inc. INZY · Entity 77717 GrantStock Option (right to buy) · Derivative 28,000 $0.00 Strike: $4.40 $0.00
Disclosure

SEC source: 0000950170-24-075631 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2034-06-17

F1 · derivative.exercise_date: The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

Read SEC document
June 18, 2024 Filed Jun 21, 2024 01:43 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 GrantRestricted Stock Units · Derivative 4,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-075835 · ownership.xml · derivative · entry 2

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

Read SEC document
June 18, 2024 Filed Jun 21, 2024 01:43 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 GrantStock Option (right to buy) · Derivative 14,000 $0.00 Strike: $41.39 $0.00
Disclosure

SEC source: 0000950170-24-075835 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2034-06-17

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:40 UTC Trevi Therapeutics, Inc. TRVI · Entity 4387 GrantNonstatutory Stock Option (right to buy) · Derivative 30,000 $0.00 Strike: $2.77 $0.00
Disclosure

SEC source: 0000950170-24-073751 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: This option was granted on June 13, 2024. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

Read SEC document
April 22, 2024 Filed Apr 24, 2024 21:00 UTC Korro Bio, Inc. KRRO · Entity 6388 PurchaseCommon Stock 17,857 $56.00 $999,992.00
Disclosure

SEC source: 0000950170-24-047681 · ownership.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 1,090,793

F1 · kind: Acquired from the Issuer on April 22, 2024 pursuant to a Subscription Agreement dated April 17, 2024.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
April 08, 2024 Filed Apr 10, 2024 23:21 UTC NeueHealth, Inc. NEUE · Entity 74308 PurchaseWarrant (Right to Buy) · Derivative 371,187 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0000950170-24-043488 · ownership.xml · derivative · entry 2

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 4

Disclosed balance after: 371,187

Underlying: Common Stock · 371,187 shares

Expires not disclosed

F2 · price: Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto.

F1 · derivative.exercise_date: Pursuant to the Warrantholders Agreement ("Warrantholders Agreement"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the "Closing Date"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.

F1 · derivative.expiration_date: Pursuant to the Warrantholders Agreement ("Warrantholders Agreement"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the "Closing Date"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.

F4 · ownership.nature: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
April 08, 2024 Filed Apr 10, 2024 23:21 UTC NeueHealth, Inc. NEUE · Entity 74308 PurchaseWarrant (Right to Buy) · Derivative 123,729 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0000950170-24-043488 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 3

Disclosed balance after: 123,729

Underlying: Common Stock · 123,729 shares

Expires not disclosed

F2 · price: Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto.

F1 · derivative.exercise_date: Pursuant to the Warrantholders Agreement ("Warrantholders Agreement"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the "Closing Date"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.

F1 · derivative.expiration_date: Pursuant to the Warrantholders Agreement ("Warrantholders Agreement"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the "Closing Date"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.

F3 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
December 19, 2023 Filed Dec 21, 2023 22:01 UTC NeueHealth, Inc. BHG · Entity 74308 PurchaseWarrant (Right to Buy) · Derivative 175,525 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0001209191-23-059454 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 1,656,789

Underlying: Common Stock · 175,525 shares

Expires 2028-08-29

F1 · price: Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE.

F2 · ownership.nature: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
October 31, 2023 Filed Nov 2, 2023 22:48 UTC NeueHealth, Inc. BHG · Entity 74308 PurchaseWarrant (Right to Buy) · Derivative 100,606 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0001209191-23-054217 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 1,481,264

Underlying: Common Stock · 100,606 shares

Expires 2028-08-29

F1 · price: Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE.

F2 · ownership.nature: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
September 15, 2023 Filed Sep 19, 2023 22:26 UTC NeueHealth, Inc. BHG · Entity 74308 PurchaseWarrant (Right to Buy) · Derivative 552,263 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0001209191-23-050065 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 1,380,658

Underlying: Common Stock · 552,263 shares

Expires 2028-08-29

F1 · price: Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE.

F2 · ownership.nature: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
August 11, 2023 Filed Aug 16, 2023 01:58 UTC NeueHealth, Inc. BHG · Entity 74308 PurchaseWarrant (Right to Buy) · Derivative 828,395 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0001209191-23-045937 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 3

Disclosed balance after: 828,395

Underlying: Common Stock · 828,395 shares

Expires not disclosed

F2 · price: Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE.

F1 · derivative.exercise_date: Pursuant to the Warrantholders Agreement ("Warrantholders Agreement"), dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity L.P. ("NEA 18 VGE"), the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the "Closing Date"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.

F1 · derivative.expiration_date: Pursuant to the Warrantholders Agreement ("Warrantholders Agreement"), dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity L.P. ("NEA 18 VGE"), the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the "Closing Date"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.

F3 · ownership.nature: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
July 17, 2023 Filed Jul 19, 2023 23:10 UTC Savara Inc SVRA · Entity 4900 PurchaseCommon Stock 333,333 $3.00 $999,999.00
Disclosure

SEC source: 0001209191-23-042802 · doc4.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note 2

Disclosed balance after: 24,471,264

F1 · kind: Reports the purchase of shares in the underwritten public offering of common stock of the Issuer.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"). NEA 17 is the sole member of Growth Equity Opportunities 17, LLC ("GEO 17"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by GEO 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
June 28, 2023 Filed Jun 30, 2023 20:14 UTC Trevi Therapeutics, Inc. TRVI · Entity 4387 GrantNonstatutory Stock Option (right to buy) · Derivative 30,000 $0.00 Strike: $2.27 $0.00
Disclosure

SEC source: 0001209191-23-040303 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-27

F1 · derivative.exercise_date: This option was granted on June 28, 2023. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

Read SEC document
June 22, 2023 Filed Jun 26, 2023 19:46 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $0.50 $0.00
Disclosure

SEC source: 0001209191-23-039666 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-22

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:58 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 GrantRestricted Stock Units · Derivative 3,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-039436 · doc4.xml · derivative · entry 2

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:58 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 GrantStock Option (right to buy) · Derivative 14,000 $0.00 Strike: $18.47 $0.00
Disclosure

SEC source: 0001209191-23-039436 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-20

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 16, 2023 Filed Jun 21, 2023 23:24 UTC Senti Biosciences Holdings, Inc. SNTI · Entity 7935 GrantStock Option (Right to Buy) · Derivative 62,500 $0.00 Strike: $0.99 $0.00
Disclosure

SEC source: 0001209191-23-038925 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2033-06-15

F1 · derivative.exercise_date: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2024 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
June 13, 2023 Filed Jun 15, 2023 16:16 UTC Inozyme Pharma, Inc. INZY · Entity 77717 GrantStock Option (right to buy) · Derivative 16,000 $0.00 Strike: $6.18 $0.00
Disclosure

SEC source: 0001209191-23-037320 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2033-06-12

F1 · derivative.exercise_date: The option was granted on June 13, 2023. The shares underlying the option are scheduled to vest as to 100% of the shares on June 13, 2024, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

Read SEC document
June 06, 2023 Filed Jun 9, 2023 00:09 UTC OnKure Therapeutics, Inc. RPHM · Entity 6550 GrantStock Option (right to buy) · Derivative 17,500 $0.00 Strike: $9.01 $0.00
Disclosure

SEC source: 0001209191-23-035585 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2033-06-05

F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
March 02, 2023 Filed Mar 6, 2023 18:47 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 OtherCommon Stock 5,771 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016175 · doc4.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 2

Disclosed balance after: 5,771

F1 · kind: The Edward Timothy Mathers Revocable Trust (the "Mathers Trust") received 5,771 shares of Common Stock of the Issuer in the distribution by NEA Partners 13, L.P. on March 2, 2023.

F2 · ownership.nature: The Reporting Person is the trustee of the Mathers Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, or otherwise of such portion of the securities held by the Mathers Trust in which the Reporting Person has no pecuniary interest.

Read SEC document
December 01, 2022 Filed Dec 2, 2022 17:09 UTC Akouos, Inc. AKUS · Entity 11574 Disposition to issuerStock Option (right to buy) · Derivative 16,000 Not disclosed Strike: $4.21 Not disclosed
Disclosure

SEC source: 0001209191-22-059455 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2032-06-22

F1 · price: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and [Continued on Note 2]

F2 · price: [Continuation of Note 1] (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.

F1 · derivative.exercise_date: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and [Continued on Note 2]

F2 · derivative.exercise_date: [Continuation of Note 1] (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.

Read SEC document
October 17, 2022 Filed Oct 19, 2022 23:59 UTC NeueHealth, Inc. BHG · Entity 74308 PurchaseSeries B Convertible Perpetual Preferred Stock · Derivative 100,000 $1,000.00 $100,000,000.00
Disclosure

SEC source: 0001209191-22-054144 · doc4.xml · derivative · entry 2

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 5

Disclosed balance after: 100,000

Underlying: Common Stock · 70,574,720 shares

Expires not disclosed

F1 · derivative.exercise_price: The Issuer's Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock ("Common Stock") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash ("compounded dividends")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments.

F1 · price: The Issuer's Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock ("Common Stock") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash ("compounded dividends")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments.

F1 · derivative.exercise_date: The Issuer's Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock ("Common Stock") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash ("compounded dividends")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments.

F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Series B Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]

F3 · derivative.expiration_date: [Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date.

F5 · ownership.nature: The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
October 17, 2022 Filed Oct 19, 2022 23:59 UTC NeueHealth, Inc. BHG · Entity 74308 PurchaseSeries B Convertible Perpetual Preferred Stock · Derivative 37,700 $1,000.00 $37,700,000.00
Disclosure

SEC source: 0001209191-22-054144 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 4

Disclosed balance after: 37,700

Underlying: Common Stock · 26,606,669 shares

Expires not disclosed

F1 · derivative.exercise_price: The Issuer's Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock ("Common Stock") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash ("compounded dividends")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments.

F1 · price: The Issuer's Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock ("Common Stock") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash ("compounded dividends")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments.

F1 · derivative.exercise_date: The Issuer's Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock ("Common Stock") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash ("compounded dividends")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments.

F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Series B Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]

F3 · derivative.expiration_date: [Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date.

F4 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
July 13, 2022 Filed Jul 15, 2022 22:09 UTC Senti Biosciences Holdings, Inc. SNTI · Entity 7935 GrantStock Option (Right to Buy) · Derivative 125,000 $0.00 Strike: $1.75 $0.00
Disclosure

SEC source: 0001209191-22-042301 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-07-12

F1 · derivative.exercise_date: The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 13, 2022, subject to the reporting person's continued service through the applicable vesting date. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2022 Equity Incentive Plan with the U.S. Securities and Exchange Commission.

Read SEC document
June 23, 2022 Filed Jun 23, 2022 21:04 UTC Trevi Therapeutics, Inc. TRVI · Entity 4387 GrantNonstatutory Stock Option (right to buy) · Derivative 20,000 $0.00 Strike: $2.27 $0.00
Disclosure

SEC source: 0001209191-22-038976 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

Read SEC document
June 23, 2022 Filed Jun 27, 2022 17:08 UTC Akouos, Inc. AKUS · Entity 11574 GrantStock Option (right to buy) · Derivative 16,000 $0.00 Strike: $4.21 $0.00
Disclosure

SEC source: 0001209191-22-039500 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders.

Read SEC document
June 10, 2022 Filed Jun 14, 2022 16:32 UTC Inozyme Pharma, Inc. INZY · Entity 77717 GrantStock Option (right to buy) · Derivative 9,367 $0.00 Strike: $4.38 $0.00
Disclosure

SEC source: 0001209191-22-036697 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,367

Underlying: Common Stock · 9,367 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:45 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 27,000 $0.00 Strike: $1.17 $0.00
Disclosure

SEC source: 0001209191-22-036358 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee-director's continued service as a director of the Corporation.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:35 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $4.15 $0.00
Disclosure

SEC source: 0001209191-22-035920 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 8, 2023 or (ii) the date of the Issuer's next annual meeting of the stockholders.

Read SEC document
June 02, 2022 Filed Jun 6, 2022 22:23 UTC Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 GrantStock Option (right to buy) · Derivative 17,000 $0.00 Strike: $23.51 $0.00
Disclosure

SEC source: 0001209191-22-034671 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2032-06-01

F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting.

Read SEC document
June 01, 2022 Filed Jun 3, 2022 21:26 UTC OnKure Therapeutics, Inc. RPHM · Entity 6550 GrantStock Option (right to buy) · Derivative 17,500 $0.00 Strike: $2.09 $0.00
Disclosure

SEC source: 0001209191-22-034225 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-05-31

F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of the stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
April 11, 2022 Filed Apr 13, 2022 21:32 UTC Trevi Therapeutics, Inc. TRVI · Entity 4387 GrantPre-Funded Warrants · Derivative 3,000,000 $1.90 Strike: $0.00 $5,697,000.00
Disclosure

SEC source: 0001209191-22-024323 · doc4.xml · derivative · entry 2

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 2

Disclosed balance after: 3,000,000

Underlying: Common Stock · 3,000,000 shares

Expires not disclosed

F1 · kind: Acquired from the Issuer on April 11, 2022 pursuant to a Securities Purchase Agreement dated April 6, 2022.

F3 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and will be exercisable until exercised in full. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 9.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise, which percentage may be increased or decreased at the holder's election upon 61 days' notice to the Issuer, not to exceed 19.99%.

F3 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and will be exercisable until exercised in full. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 9.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise, which percentage may be increased or decreased at the holder's election upon 61 days' notice to the Issuer, not to exceed 19.99%.

F2 · ownership.nature: The Reporting Person is a manager of NEA 18 VG GP, LLC, which is the sole general partner of NEA Partners 18 VG, L.P. ("NEA Partners 18 VG"). NEA Partners 18 VG is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
April 11, 2022 Filed Apr 13, 2022 21:32 UTC Trevi Therapeutics, Inc. TRVI · Entity 4387 GrantCommon Stock 948,948 $1.90 $1,803,001.20
Disclosure

SEC source: 0001209191-22-024323 · doc4.xml · nonDerivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 2

Disclosed balance after: 948,948

F1 · kind: Acquired from the Issuer on April 11, 2022 pursuant to a Securities Purchase Agreement dated April 6, 2022.

F2 · ownership.nature: The Reporting Person is a manager of NEA 18 VG GP, LLC, which is the sole general partner of NEA Partners 18 VG, L.P. ("NEA Partners 18 VG"). NEA Partners 18 VG is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Read SEC document
June 28, 2021 Filed Jun 30, 2021 22:06 UTC Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 ConversionSeries C convertible preferred Stock · Derivative 2,361,912 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-044044 · doc4.xml · derivative · entry 7

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 2

Disclosed balance after: 0

Underlying: Common Stock · 669,002 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document
June 28, 2021 Filed Jun 30, 2021 22:06 UTC Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 ConversionSeries B convertible preferred stock · Derivative 11,500,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-044044 · doc4.xml · derivative · entry 6

Mathers Edward T · CIK 0001328625 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 2

Disclosed balance after: 0

Underlying: Common Stock · 3,257,328 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.